Pharmaceutical company Alliance Pharma said it has a “healthy pipeline” of acquisition opportunities as it updated shareholders today at its AGM.

Drug discovery and development company e-Therapeutics expects to see the first findings from its new programme of clinical trials before the end of this year.

Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.

Gene therapy specialist Silence Therapeutics said data for its anti-cancer drug ‘strongly indicates’ disease stabilisation and safety in terminal cancer patients.

Regenerative tissue specialist Tissue Regenix has completed a preclinical trial on a new replacement cartilage with results due later this year.

Shares in GlaxoSmithKline fell in morning trade after it went hostile with its bid to acquire the American biotech Human Genome Sciences.

Gene therapy specialist Silence Therapeutics could earn substantially more in royalties and milestone payments after partner Quark Pharmaceuticals renegotiated a research deal with drug giant Pfizer.

The stem cell specialist ReNeuron said it had successfully raised over £6 million to fund its ongoing research and development programme.

Chief executive Glyn Edwards told Proactive Investors it was an "important milestone" for the company. The phase I study will test the safety and tolerability of an oral formulation of Summit’s SMT C1100 

The drug discovery group Summit Corporation (LON:SUMM) has received the green light for human trials of its potentially breakthrough treatment for Duchenne Muscular Dystrophy.

Plenty of ageing ex-sportsmen would like nothing more than new bit of cartilage to ease an aching knee, but that could be just the start of a whole range of new body parts Tissue Regenix may be able to supply using its new cell washing technology. 

GlaxoSmithKline’s $2.6 billion hostile bid for Human Genome Science yesterday highlighted the commercial potential for biotech ImmuPharma's rival lupus drug, Lupuzor, suggest analysts.

Plant Impact announced that the United States Environmental Protection Agency (EPA) has registered tagetes oil, a primary component of BugOil, as a new active ingredient in the United States for use on food crops.

The group's transformation in the past year could catapult it into the realms of the mid-caps if all goes to plan.

Drug discovery specialist ImmuPharma this morning said it is in discussions with a “number of companies” interested in jointly developing its breakthrough drug Lupuzor.

Sphere Medical said this morning that commercial partnering of its breakthrough Proxima Generation 3 blood analyser “remains the core objective of the current year”.

Silence Therapeutics said one of its priorities this year is to sign an out-licensing, or co-development agreement for its cancer drug candidate Atu027, or Atu111 for acute lung injury.

Plethora Solutions this morning said it was delighted by the initial response to its first regulatory submissions for PSD502, a treatment for premature ejaculation. Investors also greeted the news, sending the stock higher.

Plethora Solutions this morning said it was delighted by the initial response to its first regulatory submissions for PSD502, a treatment for premature ejaculation.

Compounds it is developing to combat Alzheimer’s have shown the ability to penetrate the Blood Brain Barrier, a major obstacle for any drugs group developing treatments that have to act in the brain.

Very rarely does a small drug company have the opportunity to do the same transaction twice – with every prospect of getting an even better deal the second time around. But this is exactly what has happened with ImmuPharma.

A multi-billion dollar trans-Atlantic takeover battle is having a particularly positive impact on a small but emerging player in the arena of stem cell research. AIM-listed Epistem has seen its share price jump 17 per cent in just over a month.

The pharmaceuticals sector will continue to outperform this year after a stellar 2011, according to research from Berenberg Bank

Sphere Medical’s Pelorus 1000 blood monitor has the potential to “significantly improve” the accuracy of dosing patients receiving the anaesthetic propofol, according to a study carried out at the Queen Elizabeth Hospital, Birmingham.

Biopharmaceutical firm Medgenics is poised to announce major progress for its novel protein delivery system, the Biopump, according to chief executive and president Dr Andrew Pearlman.

We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Thursday (February 9). We have ImmuPharma and Oxford Pharmascience presenting alongside Seeing Machines and Probability.

Landing the patent means that ValiRx can start marketing the product to the oncology research industry and fellow drug developers, while planning a larger product launch into the wider market.

Sphere Medical enjoyed a successful IPO in November and the company is now set fair for a dazzling future. But this is after years of uncertainty, and even just a few months ago the company was within days of running out of money. Jenny Chapman of Cambridge Business went to see founder and chief executive Stuart Hendry to hear the gory details.

ReNeuron said that its lead CTX neural stem cell line held up well under large-scale manufacturing conditions. The stress tests were carried out by professor Mike Hoare and his team at University College London.